VectorY Therapeutics has secured €129m ($138m) in a Series A funding round to progress the development of its vectorised antibody programmes in neurodegenerative diseases. 

EQT Life Sciences and Forbion Growth Opportunities Fund jointly led the financing round.

Participants comprised new and current investors, including the MRL Ventures Fund, Insight Partners, the ALS Investment Fund and Forbion Ventures.

VectorY plans to utilise the funding to support the clinical development of its lead programme, VTx-002.

VTx-002 is a vectorised antibody programme that acts on TDP-43. It will be progressed to treat amyotrophic lateral sclerosis (ALS) alongside the preclinical development of programmes targeting proteinopathies linked to neurodegenerative ailments.

Forbion general partner Wouter Joustra, EQT Life Sciences director Arno de Wilde and MRL Ventures Fund partner Karin Kleinhans will join VectorY’s board of directors.

VectorY CEO Sander van Deventer stated: “The Series A financing, supported by such a strong syndicate of European and US investors, is an endorsement of our pioneering approach, world-class team and commitment to bring much-needed therapies to patients with neurodegenerative diseases. 

“The investment will enable us to advance our lead programme VTx-002, a potentially disease-modifying therapy for ALS, into clinical development.”